KoBioLabs고바이오랩
348150 · KOSDAQ · ₩348150 · 고바이오랩
₩2,720▼ ₩30 (1.09%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 75.0% | 73.7% | 68.5% | 71.6% | 69.1% | 66.0% |
| Operating margin | −10.7% | −13.9% | −10.1% | −55.7% | −174.8% | −564.7% |
| Net margin | −6.4% | −9.1% | −7.8% | −41.8% | −188.9% | −531.6% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +8.8% | +1.4% | +106.3% | +185.5% | +301.1% | — |
| Operating income growth | +16.4% | −39.8% | +62.6% | +9.0% | −24.2% | — |
| Net income growth | +24.1% | −19.5% | +61.8% | +36.8% | −42.5% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −15.7% | −18.0% | −12.8% | −22.7% | −26.1% | −17.0% |
| Return on assets | −5.2% | −7.2% | −4.3% | −12.7% | −20.4% | −14.6% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 102.6% | 85.2% | 84.0% | 85.4% | 29.8% | 16.2% |
| Net debt to equity | −67.5% | −66.3% | −71.0% | −92.2% | −4.6% | −57.7% |
| Current ratio | 338.5% | 449.5% | 482.4% | 358.0% | 1,145.8% | 1,441.8% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: KoBioLabs / 고바이오랩 / 348150 / KRX:348150
Source: KRX statistical information